CN116098887A - 用于治疗史密斯-马吉利综合征的他司美琼 - Google Patents
用于治疗史密斯-马吉利综合征的他司美琼 Download PDFInfo
- Publication number
- CN116098887A CN116098887A CN202310255914.1A CN202310255914A CN116098887A CN 116098887 A CN116098887 A CN 116098887A CN 202310255914 A CN202310255914 A CN 202310255914A CN 116098887 A CN116098887 A CN 116098887A
- Authority
- CN
- China
- Prior art keywords
- tasimelteon
- sleep
- improvement
- melatonin
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PTOIAAWZLUQTIO-GXFFZTMASA-N tasimelteon Chemical compound CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2 PTOIAAWZLUQTIO-GXFFZTMASA-N 0.000 title claims abstract description 43
- 229960000660 tasimelteon Drugs 0.000 title claims abstract description 38
- 208000011580 syndromic disease Diseases 0.000 title abstract description 7
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229960003987 melatonin Drugs 0.000 claims abstract description 52
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 52
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 208000019116 sleep disease Diseases 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 3
- 230000007958 sleep Effects 0.000 claims description 29
- 230000006872 improvement Effects 0.000 claims description 12
- 206010062519 Poor quality sleep Diseases 0.000 claims description 6
- 206010041349 Somnolence Diseases 0.000 claims description 5
- 230000006399 behavior Effects 0.000 claims description 5
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 4
- 230000000422 nocturnal effect Effects 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 201000001388 Smith-Magenis syndrome Diseases 0.000 description 29
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 10
- 229960000890 hydrocortisone Drugs 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 239000000556 agonist Substances 0.000 description 5
- 230000002060 circadian Effects 0.000 description 5
- 230000027288 circadian rhythm Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010001488 Aggression Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000030979 Language Development disease Diseases 0.000 description 2
- 101150063503 RAI1 gene Proteins 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 208000012761 aggressive behavior Diseases 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008632 circadian clock Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000013651 non-24-hour sleep-wake syndrome Diseases 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000004461 rapid eye movement Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TYNMOIYXEIAPHL-UHFFFAOYSA-N 2-(3-hydroxypropyl)phenol Chemical class OCCCC1=CC=CC=C1O TYNMOIYXEIAPHL-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101001013797 Homo sapiens Metallothionein-1L Proteins 0.000 description 1
- 101001088739 Homo sapiens Probable inactive ribonuclease-like protein 12 Proteins 0.000 description 1
- 101001099922 Homo sapiens Retinoic acid-induced protein 1 Proteins 0.000 description 1
- 102000001419 Melatonin receptor Human genes 0.000 description 1
- 108050009605 Melatonin receptor Proteins 0.000 description 1
- 229940121723 Melatonin receptor agonist Drugs 0.000 description 1
- 102100031782 Metallothionein-1L Human genes 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100033988 Probable inactive ribonuclease-like protein 12 Human genes 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electric Connection Of Electric Components To Printed Circuits (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
- Processing Of Solid Wastes (AREA)
- Compositions Of Oxide Ceramics (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coils Or Transformers For Communication (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Led Device Packages (AREA)
- Steroid Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462044856P | 2014-09-02 | 2014-09-02 | |
| US62/044,856 | 2014-09-02 | ||
| US201562169635P | 2015-06-02 | 2015-06-02 | |
| US62/169,635 | 2015-06-02 | ||
| CN201580046852.7A CN106604726A (zh) | 2014-09-02 | 2015-08-29 | 用于治疗史密斯‑马吉利综合征的他司美琼 |
| PCT/US2015/047610 WO2016036619A1 (en) | 2014-09-02 | 2015-08-29 | Tasimelteon for treating smith-magenis syndrome |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580046852.7A Division CN106604726A (zh) | 2014-09-02 | 2015-08-29 | 用于治疗史密斯‑马吉利综合征的他司美琼 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116098887A true CN116098887A (zh) | 2023-05-12 |
Family
ID=54147267
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310255914.1A Pending CN116098887A (zh) | 2014-09-02 | 2015-08-29 | 用于治疗史密斯-马吉利综合征的他司美琼 |
| CN201580046852.7A Pending CN106604726A (zh) | 2014-09-02 | 2015-08-29 | 用于治疗史密斯‑马吉利综合征的他司美琼 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580046852.7A Pending CN106604726A (zh) | 2014-09-02 | 2015-08-29 | 用于治疗史密斯‑马吉利综合征的他司美琼 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US10179119B2 (enExample) |
| EP (2) | EP4137129A1 (enExample) |
| JP (3) | JP6903571B2 (enExample) |
| KR (2) | KR20240015729A (enExample) |
| CN (2) | CN116098887A (enExample) |
| AU (2) | AU2015312252B2 (enExample) |
| BR (1) | BR112017003644A2 (enExample) |
| CA (2) | CA3124872A1 (enExample) |
| DK (1) | DK3188727T3 (enExample) |
| ES (1) | ES2936833T3 (enExample) |
| FI (1) | FI3188727T3 (enExample) |
| HR (1) | HRP20230070T1 (enExample) |
| HU (1) | HUE061051T2 (enExample) |
| MX (1) | MX386150B (enExample) |
| PT (1) | PT3188727T (enExample) |
| SI (1) | SI3188727T1 (enExample) |
| WO (1) | WO2016036619A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2488392C2 (ru) * | 2006-05-22 | 2013-07-27 | Ванда Фармасьютиклз, Инк. | Лечение агонистом мелатонина |
| SI3188727T1 (sl) * | 2014-09-02 | 2023-03-31 | Vanda Pharmaceuticals Inc. | Tasimelteon za zdravljenje Smith-Magenisovega sindroma |
| BR112020017886A2 (pt) * | 2018-03-04 | 2021-03-23 | Vanda Pharmaceuticals Inc. | métodos para tratar um indivíduo experienciando um avanço na interrupção do ciclo de dormir-despertar na hora de dormir estabelecida do indivíduo, para tratar jet lag em um indivíduo e para reduzir uma consequência indesejada de um avanço de até oito horas em uma hora de dormir estabelecida do indivíduo, e, unidade de dispensação pré-empacotada |
| WO2020056117A1 (en) * | 2018-09-12 | 2020-03-19 | Vanda Pharmaceuticals Inc.. | Improving sleep or post-sleep performance |
| JP7503632B2 (ja) | 2019-12-13 | 2024-06-20 | バンダ・ファーマシューティカルズ・インコーポレイテッド | 液体タシメルテオン製剤及びそれを使用する方法 |
| JP7628127B2 (ja) | 2020-08-27 | 2025-02-07 | 株式会社ヨコオ | 検査装置 |
| AU2022345260A1 (en) * | 2021-09-14 | 2024-04-04 | Vanda Pharmaceuticals Inc. | Treatment of sleep disturbances in autism spectrum disorder patients |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130197076A1 (en) * | 2012-01-26 | 2013-08-01 | Vanda Pharmaceuticals, Inc. | Treatment of circadian rhythm disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9711051B (en) | 1996-12-10 | 1999-06-09 | Bristol Myers Squibb Co | Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents |
| US20050137247A1 (en) | 2003-12-22 | 2005-06-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of hypertension |
| US7754902B2 (en) | 2006-05-18 | 2010-07-13 | Vanda Pharmaceuticals, Inc. | Ruthenium(II) catalysts for use in stereoselective cyclopropanations |
| RU2488392C2 (ru) | 2006-05-22 | 2013-07-27 | Ванда Фармасьютиклз, Инк. | Лечение агонистом мелатонина |
| US20080260837A1 (en) | 2007-04-20 | 2008-10-23 | Qpharma, L.L.C. | Physically stable aqueous suspensions of active pharmaceuticals |
| KR100928515B1 (ko) | 2008-04-02 | 2009-11-26 | 주식회사 동부하이텍 | 데이터 수신 장치 |
| WO2011009102A1 (en) | 2009-07-16 | 2011-01-20 | Vanda Pharmaceuticals Inc. | Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia |
| CN102675268A (zh) * | 2012-05-18 | 2012-09-19 | 济南志合医药科技有限公司 | 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法 |
| US10376487B2 (en) * | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
| SI3188727T1 (sl) * | 2014-09-02 | 2023-03-31 | Vanda Pharmaceuticals Inc. | Tasimelteon za zdravljenje Smith-Magenisovega sindroma |
| JP7503632B2 (ja) * | 2019-12-13 | 2024-06-20 | バンダ・ファーマシューティカルズ・インコーポレイテッド | 液体タシメルテオン製剤及びそれを使用する方法 |
-
2015
- 2015-08-29 SI SI201531919T patent/SI3188727T1/sl unknown
- 2015-08-29 ES ES15766274T patent/ES2936833T3/es active Active
- 2015-08-29 FI FIEP15766274.3T patent/FI3188727T3/fi active
- 2015-08-29 HU HUE15766274A patent/HUE061051T2/hu unknown
- 2015-08-29 EP EP22199492.4A patent/EP4137129A1/en active Pending
- 2015-08-29 HR HRP20230070TT patent/HRP20230070T1/hr unknown
- 2015-08-29 JP JP2017512287A patent/JP6903571B2/ja active Active
- 2015-08-29 PT PT157662743T patent/PT3188727T/pt unknown
- 2015-08-29 CN CN202310255914.1A patent/CN116098887A/zh active Pending
- 2015-08-29 WO PCT/US2015/047610 patent/WO2016036619A1/en not_active Ceased
- 2015-08-29 CA CA3124872A patent/CA3124872A1/en active Pending
- 2015-08-29 DK DK15766274.3T patent/DK3188727T3/da active
- 2015-08-29 CN CN201580046852.7A patent/CN106604726A/zh active Pending
- 2015-08-29 US US15/326,934 patent/US10179119B2/en active Active
- 2015-08-29 CA CA2957588A patent/CA2957588C/en active Active
- 2015-08-29 MX MX2017002796A patent/MX386150B/es unknown
- 2015-08-29 KR KR1020247002426A patent/KR20240015729A/ko active Pending
- 2015-08-29 AU AU2015312252A patent/AU2015312252B2/en active Active
- 2015-08-29 EP EP15766274.3A patent/EP3188727B1/en active Active
- 2015-08-29 BR BR112017003644A patent/BR112017003644A2/pt not_active Application Discontinuation
- 2015-08-29 KR KR1020177009052A patent/KR20170048541A/ko not_active Ceased
-
2018
- 2018-12-06 US US16/211,687 patent/US10653665B2/en active Active
-
2020
- 2020-04-14 US US16/848,150 patent/US11266622B2/en active Active
- 2020-06-04 JP JP2020097599A patent/JP7132277B2/ja active Active
- 2020-09-22 AU AU2020239640A patent/AU2020239640B2/en active Active
-
2022
- 2022-01-14 US US17/648,046 patent/US20220133681A1/en not_active Abandoned
- 2022-03-14 JP JP2022039475A patent/JP7252390B2/ja active Active
-
2024
- 2024-05-08 US US18/658,100 patent/US20240293355A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130197076A1 (en) * | 2012-01-26 | 2013-08-01 | Vanda Pharmaceuticals, Inc. | Treatment of circadian rhythm disorders |
Non-Patent Citations (3)
| Title |
|---|
| SANCHEZ-BARCELO, E. J.，等: "Clinical uses of melatonin: evaluation of human trials", CURRENT MEDICINAL CHEMISTRY, vol. 17, no. 19, 1 July 2010 (2010-07-01), pages 2085, XP055113550, DOI: 10.2174/092986710791233689 * |
| STEPHEN M STAHL: "《Stahl’s Essential Psychopharmacology-Neuroscientific Basis and Practical Application, Fourth Edition》", 31 December 2013, CAMBRIDGE UNIVERSITY PRESS, pages: 457 * |
| 黄培新等主编: "《神经科专病中医治疗》", 31 October 2013, 人民卫生出版社, pages: 480 - 482 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020239640B2 (en) | Tasimelteon for treating smith-magenis syndrome | |
| JP2023103375A (ja) | ガボキサドールでの発達障害の処置方法 | |
| Yukuhiro et al. | Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys | |
| JP2021181465A (ja) | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 | |
| Ray et al. | Effects of the second-generation" bath salt" cathinone alpha-pyrrolidinopropiophenone (α-PPP) on behavior and monoamine neurochemistry in male mice | |
| US20140163050A1 (en) | Use of 1H-quinazoline-2,4-diones | |
| CN112367998B (zh) | 用组胺-3受体反向激动剂进行治疗的方法 | |
| NZ765911B2 (en) | Tasimelteon for treating smith-magenis syndrome | |
| NZ729901B2 (en) | Tasimelteon for treating smith-magenis syndrome | |
| García-Barba et al. | Serotonin receptor antagonists increase fast ripple activity in rats treated with kainic acid | |
| AU2011376333A1 (en) | Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy | |
| Deodhar | Development and Characterization of Pre-Clinical Epilepsy Models to Evaluate Potential Anti-Seizure Targets | |
| CA3247785A1 (en) | USE OF 5-HT1A SEROTONIN RECEPTOR AGONISTS TO TREAT DISEASES ASSOCIATED WITH SUDDEN UNSURPRISED DEATH IN EPILEPSY | |
| KR20100055428A (ko) | 수면 장애의 치료 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |